ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Institutional ownership has grown in the past 6 months. An activist investor is watching ADMA intently.

ADMA: Pertinent Updates

ADiTx Therapeutics

Clovis Oncology

Can these penny stocks continue to climb after a bearish trading day? The post Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn

RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation and exclusive Key Opinion Leader symposium by nationally recognized clinical experts on the management of respiratory viral infections (RVIs) and real-world experience with ADMA's ASCENIV, a U.S. Food and Drug Administration (FDA)-approved intravenous immunoglobulin (IVIG) product with a unique composition.

ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

ADMA reported full-year 2021 numbers on March 24, which disclosed higher than expected revenue, a lower than expected net loss, and strong 2022 guidance.

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Agrify

Creative Medical Technology Holdings

Are these penny stocks on your April watchlist? The post Top Must-Watch Penny Stocks For Your April List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Must-Watch Penny Stocks For Your April List

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022. The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the.

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing

ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020

ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET

ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth  Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by year-end 2023

ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

Dare Bioscience

Oncolytics Biotech, Inc.

ReTo Eco-Solutions

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $4 Right Now

ADMA Biologics Inc (NASDAQ: ADMA) expects Q4 Sales of approximately $26 million, compared to $14 million a year ago and better than the consensus of $21.76 million.  The preliminary results represent the Company's highest quarterly revenue since its inception.

ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation

Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception

ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

2021 was a difficult time to be an ADMA shareholder with dilution having a significant impact on ADMA's stock price.

ADMA Biologics: 2021 Was Tough

FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023

ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a 6-month term stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one right (the “Right”) for each outstanding share of common stock. The record date for the dividend distribution is December 30, 2021. The Rights Plan will expire, without any further action required to be taken by ADMA's Board of Directors, on June 15, 2022.

ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options

Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin

ADMA Biologics Provides Update on Global Intellectual Property Portfolio

On November 10th, ADMA reported a great quarter. Revenue grew to $20.68M, up 101.2% y/y, and the Company reached a number of milestones.

ADMA Biologics: Turning A Corner

New Oriental Education & Technology Group

Stran & Co

Check these penny stocks out for your watchlist The post Are These Penny Stocks on Your Watchlist Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Penny Stocks on Your Watchlist Right Now?

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Cyndi Tolman, ADMA's Senior Vice President of Plasma Services, has been elected to serve on the PPTA Source Board of Directors (“PPTA Source Board”) for the 2022 to 2024 election term.

ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors

ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction

ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC

ADMA Biologics Inc (NASDAQ: ADMA) achieved Q3 sales of $20.7 million, + 101% Y/Y, beating the consensus of $18.72 million. The increase was favorably impacted by the continued commercial ramp-up of ADMA's intravenous immune globulin (IVIG) product portfolio and the sale of intermediate fractions.

ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q3 2021 Results - Earnings Call Transcript

Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020

News for ADMA Biologics Stock (ADMA)